Darnisha Grant Harrison is the Founder, President & CEO of Ennaid Therapeutics. As the company’s Head, she is responsible for guiding the company toward its plan of being first-to-market with the world’s first therapeutic cure for two of the most notorious mosquito-borne diseases in the world, Zika virus and dengue virus.
Once a Microbiologist and Chemist, Darnisha is now a nationally recognized pharmaceutical entrepreneur by Newsweek Magazine and has greater than twenty-three years’ experience in the Life Sciences.
Prior to founding Ennaid Therapeutics in 2012, she spent three years as a scientist, most notably at Amgen and the University of Georgia, and sixteen years in Business Development/Licensing as a Director in various companies in the pharmaceutical industry. She is an accomplished negotiator and deal-maker in identifying, negotiating and closing drug development deals and strategic collaborations. Darnisha is accomplished in technology acquisition and licensing, strategic business development, business planning and brisk, successful execution of such plans. A member of the American Association for the Advancement of Science, the New York Academy of Sciences, The World Chamber of Commerce and Women In BIO, Darnisha received a B.S. in Microbiology and Minor in Chemistry from LSU.
William J. Brock is the Principal of Brock Scientific Consulting, LLC. He has about 30 years of experience as a toxicologist, manager and consultant for research and development in the pharmaceutical, consumer product, food, medical device and chemical industries. Experienced in occupational and industrial toxicology; nonclinical safety program study design, conduct, interpretation and reporting; evaluating clinical and product safety data; in training and managing staff; dealing with a wide range of U.S. and foreign regulatory bodies, commercial concerns, and contract research organizations; labeling and other regulatory compliance issues; writing reports, regulatory and toxicology position papers; presentations to regulatory authorities; risk and safety assessments and litigation support. He attended University of Kentucky in Lexington, Kentucky (1980-1983) and earned a Ph.D. in Toxicology.
George has greater than twenty years of experience in business consulting, advising successful startups and small businesses, business development, corporate affairs, strategic planning, inbound marketing and social media deployment in software and new emerging technologies. He equally has an extensive network both domestically and internationally. He holds a B. S. from Virginia Tech University in Business Administration with a concentration in Hospitality and Tourism Management.
Jason is a corporate finance professional with nearly 20 years’ experience working with health care and biopharmaceutical companies. He began a career on Wall Street in 1995 and later spent 13 years in London where he had a chance to work with companies from around the world. His specializes in licensing and M&A, capital raising and strategic budgeting and planning. He returned to his hometown of Atlanta in 2013, and now works as an independent consultant, assisting a number of local companies in matters of strategic finance. Mr. Foss is a graduate of Georgetown University (BA – Psychology) and the University of Chicago (MBA – Finance and Accounting).
Dr. Garry is the inventor of Ennaid Therapeutics’ technology and is a world-renowned Microbiologist and Virologist. Research in his laboratory focuses on a number of breakthrough discoveries in viral pathogenesis and has resulted in the development of many antiviral peptide drugs. He is currently managing programs to develop therapies/vaccines for dengue virus and lassa virus. He is the founding Editor-In-Chief of Virology Journal and has served on many NIH review panels. Dr. Garry received a Ph.D. in Microbiology and Virology from the University of Texas, Austin.
With twenty one years of experience in the pharma industry Romeo is a stellar scientist and has worked in big pharma and small start-up pharma companies. He has held positions at Abbott/now Abbvie, Sciele Pharma & Wockhardt. His expertise is in basic chemistry, tech transfer, process development and optimization, scale-up/down and validation. He has many years of experience managing outsourced development projects. Romeo has a Masters in Chemistry, a Masters in Chemical Engineering and a B.S. in Chemistry from the University of Illinois, Chicago.
Stephan Jackman is the Vice President and Chief Operating Officer for Ennaid Therapeutics and a member of the executive leadership team. He brings seventeen years of multi-industry experience in administration, business development, marketing, project/program management, and strategic planning. Stephan has a successful track record of executing large complex projects and programs from concept through implementation, creating value for internal and external stakeholders, and developing strategic alliances and cross-functions teams to meet and exceed goals. He has held positions of increasing responsibility at Novartis Pharmaceuticals, L’Oreal USA, SBM Management Services, and Family Intervention Services. Prior to joining Ennaid Therapeutics, Stephan was an independent project and management consultant assisting fortune 500 companies and non-profits with strategic initiatives. He is a champion of diversity and inclusion, having developed and led multiple affinity groups at previous organizations. Stephan has represented several organizations by serving on multiple non-profits board of directors throughout New Jersey and New York. Additionally, he is an advocate for K-12 STEM education, having spent twelve years mentoring and teaching math to “at-risk” high school students in the Kean University Upward Bound program.
Stephan received a Bachelor of Engineering in Mechanical Engineering and a Master of Science in Management from Stevens Institute of Technology, Hoboken New Jersey.
Dr. Michael is a co-inventor of Ennaid Therapeutics’ dengue peptide technology. His previous accomplishments include major discoveries on HIV protease inhibitor resistance and the origin of HIV-1 from chimpanzees. His current research interests are directed towards the development of anti-virals and vaccines against dengue virus. He serves on the editorial boards of Virology Journal and PLOS Neglected Tropical Diseases. Dr. Michael received a Ph.D. in Chemistry from the Johns Hopkins University.
With greater than thirty years of experience in the pharmaceutical and related industries, Dr. Moreton is currently the V.P. of Pharmaceutical Sciences at FinnBrit Consulting. Dr. Moreton spent the bulk of his career at Penwest Pharmaceuticals and Idenix Pharmaceuticals, where he served as VP of Pharmaceutical Sciences. His extensive expertise in the pharmaceutical industry is in preformulation, formulation and process design and development, scale-up and clinical manufacture, technical transfer to commercial manufacture, process validation, analytical method development and validation, quality assurance, excipients, GMPs for excipients, pharmaceutical finished products, nutritional products and APIs, CMC regulatory documentation, contract manufacturing and development and packaging. Dr. Moreton’s additional specialties include pharmaceutical product development, clinical manufacture, project coordination and mangement, technical transfer, CGMP and scale-up. He received a Ph.D. in Pharmaceutics from Cardiff University/Prifysgol Caerdydd.
Dr. Myeni has a background in both business and medicine. In addition to having a history in sales and logistics, she is an ophthalmologist who has completed advanced specialty training in both the medical and surgical management of glaucoma. Dr. Myeni received a Doctor of Medicine degree from the Medical College of Georgia. Thereafter, she acquired a Masters in Public Health from Harvard University, with a concentration in Health Management and she received an undergraduate degree from the Amherst College. She completed her residency training in ophthalmology at Howard University Hospital, after which she acquired a fellowship in glaucoma at Wills Eye Hospital in Philadelphia, PA. Dr. Myeni is currently a practicing Ophthalmologist in Washington, D.C.
GARY H.S. STRAUSS is a dedicated medical research scientist with doctoral and post-doctoral training in medical microbiology, immunology, medical genomics, and toxicology. A principal investigator in US and British government laboratories, as well as a research professor at a prominent US medical school, and collaborator with several biotechnology companies, he spent over twenty years conducting original research while also fulfilling requisite mentoring and administrative responsibilities. Lab work took precedence in those years as he developed new methods for measuring drug resistance and other genetically-induced and -determined responses to environmental mutagens/ carcinogens including, in many instances, medical therapies then undergoing ICH- and FDA-supervised clinical trials. In his laboratory years, he also introduced novel methods for use in stem- and differentiated cell cryopreservation and assessing immunocompetency, but he is best known as co-inventor of the seminal technology for detecting, enumerating, and monitoring mutant frequencies among somatic cells arising in-vivo and induced in-vitro. Gary received his PhD in Medical Microbiology from the U. Vermont College of Medicine, Burlington, VT and a DPhil in Genetic Toxicology from U. Sussex Medical Research Council, Brighton, UK